Currently Viewing:
Newsroom
Currently Reading
Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25, 2018 – Kaitlynn Ely
Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes
February 24, 2018 – Samantha DiGrande
Current Risk-Adjustment Approach Underpaid Insurance Carriers for Part-Year Members
February 24, 2018 – Kaitlynn Ely
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 23, 2018 – Jaime Rosenberg
Survey Examines Whether Primary Care Doctors Gave Correct ADHD Diagnosis
February 23, 2018 – Allison Inserro
This Week in Managed Care: February 23, 2018
February 23, 2018
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23, 2018 – Kelly Davio
Hydroxychloroquine Ineffective in Treating Hand Osteoarthritis Compared With Placebo
February 23, 2018 – Kaitlyn Ely
AJMC® in the Press, February 23, 2018
February 23, 2018 – AJMC Staff

Continued Statin Use Following Adverse Reaction May Reduce Incidence of Death and CVD Events

Alison Rodriguez
Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.
Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.

A new study published by the Annals of Internal Medicine evaluates the relationship between continued statin prescriptions in a 12-month period following an adverse reaction, and a subsequent cardiovascular or death. The study participants were receiving statin prescriptions and had primary care providers with Brigham and Women’s Hospital or Massachusetts General Hospital between 2000 and 2011. In addition, each participant experienced an adverse reaction, presumed to be a result of the statin, that was documented by the provider during the study period.

The data was collected from electronic medical records (EMR). The patient was categorized as continuing to receive statin prescriptions, if they received another prescription for a statin during the treatment period, and the comparison group was composed of those who did not receive statin prescriptions after the adverse reaction.

The study included 28,266 participants and 19,989 patients (70.7%) continued to receive satin prescriptions while 8277 did not. A majority (80.9%) of the adverse reactions were identified from the provider notes in the EMR, 10.8% were identified from the EMR data, and 8.3% were present in both sources.

The primary outcome was determined as the first to occur of either myocardial infarction, stroke, or death from any cause. Four years following the presumed adverse event, the total incidence of the composite primary outcome was 12.2% for patients with continued statin prescriptions and 13.9% for those without them. This suggests that statin prescriptions are associated with a lower incidence of cardiovascular events and death among those with a presumed adverse reaction.

“Whether therapy should be continued after an adverse reaction is an important decision that must take into account the balance of potential benefits and risks to the patient,” the authors concluded. “This study's findings may help patients and their clinicians inform their choice of treatment to best fit each patient's circumstances.”

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!